GSK plc (GSK) AI Stock Analysis

GSK plc specializes in the research, development, and commercialization of pharmaceuticals, vaccines, and consumer health products worldwide. Headquartered in Brentford, UK, the company operates across four key segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. Its portfolio covers therapeutic medicines for respiratory, HIV, oncology, cardiovascular, and dermatology conditions, alongside consumer healthcare products in wellness, oral health, nutrition, and skin health. GSK delivers treatments in tablets, syrups, nasal sprays, and trans-dermal patches, supported by strategic partnerships with industry peers such as Novartis, Sanofi SA, and CureVac AG.

Revenue grew at a 5-year CAGR of 6.0% from FY2020 to FY2025. Between FY2021 and FY2025, annual revenue expanded from $24.70B to $32.67B, while gross margin improved from 66.9% to 72.4%. Operating margin rose to 25.5% in FY2025 after dropping to 12.8% in FY2024, and net income recovered to $5.72B from $2.58B in FY2024. For the trailing twelve months, revenue reached $33.20B with an operating margin of 30.9% and a profit margin of 14.5%. In the latest quarter ended June 30, 2026, quarterly revenue increased 5.3% year-over-year, while quarterly earnings declined 69.5%.

As of June 30, 2026, GSK held $3.09B in cash and short-term investments against total debt of $18.13B, resulting in net debt of $15.04B. Total assets were $61.37B and shareholders' equity stood at $17.54B, with a current ratio of 0.82 and a debt-to-equity ratio of 1.03. In FY2025, operating cash flow was $7.14B and capital expenditures were $1.32B, generating free cash flow of $5.82B. Cash allocation in FY2025 included $2.51B in dividends paid and $1.36B in share buybacks, while the 5-year share count changed by -0.3%.

GSK trades at a trailing P/E of 15.6x and a forward P/E of 9.8x, both below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value to EBITDA multiple of 9.5x and price-to-sales ratio of 3.0x also sit below the peer medians of 12.0x and 4.1x. Over the past year, the stock returned 17.1%, slightly outpacing the S&P 500 return of 16.8%. Over a 5-year span, GSK returned 55.4%, trailing the S&P 500 return of 83.0%.

GSK pays a quarterly dividend with an annual forward payout of $1.82 per share, offering a dividend yield of 3.67% and a payout ratio of 38.0%. The company has paid dividends for 43 consecutive years. Its 5-year annualized dividend growth rate is -4.0%, and its most recent ex-dividend date was August 14, 2026.

Wall Street analysts hold 3 Strong Buy, 1 Buy, 4 Hold, 0 Sell, and 1 Strong Sell ratings on the stock. The mean price target is $60.51, representing a 22.2% premium over the last close of $49.51. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $33.91B and EPS of $4.72. GSK has beaten EPS estimates in 4 of its last 4 quarters, and its next earnings release is scheduled for October 28, 2026.

This page is an AI-written research summary of GSK plc (GSK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GSK income statement, GSK balance sheet, GSK analyst forecast, GSK chart. See the GSK stock overview for the latest quote and news.